Wednesday, October 31, 2018

7:00 a.m.
Registration and Breakfast
Orangedale Ballroom & Heritage 2

7:50
Welcome and Conference Overview – Day 1
Heritage Ballroom 2

8:00
WELLS Criteria Practical Application
Robert McBane, M.D.

8:15
Is Age Adjusted D-Dimer a Valid Application?
Dong Chen, M.D., Ph.D.

8:45
Ultrasound Evaluation of DVT
Nirvikar (Nirvi) Dahiya, M.D.

9:15
Thrombophilia Testing
Robert McBane, M.D.

9:30
Can I Manage this VTE as an Outpatient: Protocol Based Anticoagulation Clinics
Waldemar Wysokinski, M.D., Ph.D.

9:45
Initial Management of DVT: Which Anticoagulant for Whom
Fadi Shamoun, M.D.

10:00
Break (Exhibits Open)
Orangedale Ballroom

Breakouts

10:30
Breakout 1: WELLS Criteria/D Dimer
Robert McBane, M.D. and Dong Chen, M.D., Ph.D.
Heritage Ballroom 1

Breakout 2: Thrombophilia
Waldemar Wysokinski, M.D., Ph.D.
Heritage Ballroom 2
11:00  Breakout 1: WELLS Criteria/D Dimer  
      Robert McBane, M.D. and Dong Chen, M.D., Ph.D.  
      Heritage Ballroom 2

11:30  Breakout 2: Thrombophilia  
      Waldemar Wysokinski, M.D., Ph.D.  
      Heritage Ballroom 1

11:30  Lunch (Exhibits Open)  
      Orangedale Ballroom

1:00 p.m.  Primary DVT Prevention Updates  
           Robert McBane, M.D.

1:30  Duration of Anticoagulation (Choosing Wisely)  
      Aneel Ashrani, M.D.

2:00  Break (Exhibits Open)  
      Orangedale Ballroom

2:30  Thrombolysis: Role in PE vs. DVT  
      Haraldur Bjarnason, M.D.

3:00  Effect of Thrombolytic Therapy on Coagulation Testing  
      Dong Chen, M.D., Ph.D.

3:30  Adjournment

Thursday, November 1, 2018

7:00 a.m.  Registration and Breakfast  
          Orangedale Ballroom & Heritage 2

7:50  Welcome and Conference Overview – Day 2  
      Heritage Ballroom 2

8:00  Cancer Associated Venous-Thromboembolism: Epidemiology  
      Aneel Ashrani, M.D.

8:15  DVT Prophylaxis in the Cancer Patient  
      Leslie Padrnos, M.D.

8:30  Risk Stratification for Cancer and VTE (Biomarkers)  
      Aneel Ashrani, M.D.

9:15  How to Manage Anticoagulation Therapy: Anticoagulation Failure in Cancer Patients  
      Robert McBane, M.D.
Peri-Procedural Management of Anticoagulation in Cancer Associated VTE Patients
Waldemar Wysokinski, M.D., Ph.D.

9:45 Q & A

10:00 Break (Exhibits Open)
Orangedale Ballroom
Breakouts

10:30 Breakout 1: Case-Based Discussion on Identifying the High Risk Patient (Risk Factors and Prevention)
Aneel Ashrani, M.D. and Leslie Padrnos, M.D.
Heritage Ballroom 1

Breakout 2: Case-Based Discussion on Cancer Associated Venous Thromboembolism Anticoagulation Conundrums
Robert McBane, M.D. and Waldemar Wysokinski, M.D., Ph.D.
Heritage Ballroom 2

11:00 Breakout 1: Case-Based Discussion on Identifying the High Risk Patient (Risk Factors and Prevention)
Aneel Ashrani, M.D. and Leslie Padrnos, M.D.
Heritage Ballroom 1

Breakout 2: Case-Based Discussion on Cancer Associated Venous Thromboembolism Anticoagulation Conundrums
Robert McBane, M.D. and Waldemar Wysokinski, M.D., Ph.D.
Heritage Ballroom 2

11:30 Lunch (Exhibits Open)
Orangedale Ballroom

Treatment of Cancer Associated VT: Outcomes of Warfarin
Fadi Shamoun, M.D.

1:00 p.m.

Treatment of Cancer Associated VT: Outcomes of LMWH
Leslie Padrnos, M.D.

Treatment of Cancer Associated VT: Outcomes of DOACs
Waldemar Wysokinski, M.D., Ph.D.

1:40 Break (Exhibits Open)
Orangedale Ballroom

2:00

Venous Thrombosis: Cancer Screening
Aneel Ashrani, M.D.

Special Considerations in Anticoagulation of Cancer Patients
Ariela Marshall, M.D.

3:00 Adjournment

3:30
Continental Breakfast
Orangedale Ballroom

7:00 a.m.
Welcome and Conference Overview – Day 3
Heritage Ballroom 2

7:50
Dosing DOACs for Renal/Hepatic Impairment
Lydia Patel, Pharm.D., R.Ph.

8:00
Dosing DOACs for Obesity
Damon Houghton, M.D.

8:15
DOACs Drug Interactions
Narith Ou, Pharm.D., R.Ph.

8:30
Genotype Guided Dosing for DOACs
Christopher Grilli, Pharm.D., R.Ph.

9:15
Measurement of Drug Levels: When and Why
Waldemar Wysokinski, M.D., Ph.D.

9:45
Q & A

10:00
Break (Exhibits Open)
Orangedale Ballroom

10:30
Breakout 1: Clinical Variables Impacting DOAC Use - Renal Impairment, Obesity, Drug Interactions, Compliance
Lydia Patel, Pharm.D., R.Ph. and Damon Houghton, M.D.
Heritage Ballroom 1

Breakout 2: Laboratory Variables Impacting DOAC Use – Laboratory Monitoring, Genotype Guided Dosing, and Drug Interaction
Narith Ou, Pharm.D., R.Ph., Christopher B. Grilli, Pharm.D., R.Ph.
Heritage Ballroom 2

11:15
Breakout 1: Clinical Variables Impacting DOAC Use - Renal Impairment, Obesity, Drug Interactions, Compliance
Lydia Patel, Pharm.D., R.Ph. and Damon Houghton, M.D.
Heritage Ballroom 2

Breakout 2: Laboratory Variables Impacting DOAC Use – Laboratory Monitoring, Genotype Guided Dosing, and Drug Interaction
Narith Ou, Pharm.D., R.Ph., Christopher B. Grilli, Pharm.D., R.Ph.
Heritage Ballroom 1
12:00 p.m.  Lunch (Exhibits Open)
Orangedale Ballroom

1:00  Challenges in Transition from APTT to Anti-Xa for Monitoring Heparin: Laboratory Aspects
Narith Ou, Pharm.D., R.Ph. & Jill Adamski, M.D., Ph.D.

1:20  Laboratory Validation of Anti-Xa Assays
Rachel Leger

1:40  Laboratory Validation of DTI Assays
Julie Tange

2:00  Break (Exhibits Open)
Orangedale Ballroom

2:30  DOACs and APS/HIT
Ariela Marshall, M.D.

3:00  Reversal of DOACs and Outcomes
Waldemar Wysokinski, M.D., Ph.D.

3:30  Adjournment